Literature DB >> 19106171

Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors.

Brenda Gonzalez1, Francisco Paz, Leonor Florán, Jorge Aceves, David Erlij, Benjamín Florán.   

Abstract

The motor effects of cannabinoids in the globus pallidus appear to be caused by increases in interstitial GABA. To elucidate the mechanism of this response, we investigated the effect of the selective cannabinoid type 1 receptor (CB1) cannabinoid agonist arachidonyl-2-chloroethylamide (ACEA) on [(3)H]GABA release in slices of the rat globus pallidus. ACEA had two effects: concentrations between 10(-8) and 10(-6) M stimulated release, whereas higher concentrations (IC(50) approximately 10(-6) M) inhibited it. Another cannabinoid agonist, WIN-55,212-2, also had bimodal effects on release. Studies of cAMP production indicate that under conditions of low G(i/o), availability the coupling of CB1 receptors with G(i/o) proteins can be changed into CB1:G(s/olf) coupling; therefore, we determined the effects of conditions that limit G(i/o) availability on [(3)H]GABA release. Blockers of G(i/o) protein interactions, pertussis toxin and N-ethylmaleimide, transformed the inhibitory effects of ACEA on GABA release into stimulation. It also has been suggested that stimulation of D2 receptors can reduce G(i/o) availability. Blocking D2 receptors with sulpiride [(S)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamidersqb] or depleting dopamine with reserpine inhibited the ACEA-induced stimulation of release. Thus, the D2 dependence of stimulation is consistent with the proposal that D2 receptors reduce G(i/o) proteins available for binding to the CB1 receptor. In summary, CB1 receptor activation has dual effects on GABA release in the globus pallidus. Low concentrations stimulate release through a process that depends on activation of dopamine D2 receptors that may limit G(i/o) protein availability. Higher concentrations of cannabinoid inhibit GABA release through mechanisms that are independent of D2 receptor activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19106171     DOI: 10.1124/jpet.108.145425

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

Authors:  Concepción García; Cristina Palomo-Garo; Yolanda Gómez-Gálvez; Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

Review 2.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15

3.  The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.

Authors:  Margaret I Davis; Jill R Crittenden; Austin Y Feng; David A Kupferschmidt; Alipi Naydenov; Nephi Stella; Ann M Graybiel; David M Lovinger
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

Review 4.  Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

Authors:  Despina Kokona; Panagiota-Christina Georgiou; Mihalis Kounenidakis; Foteini Kiagiadaki; Kyriaki Thermos
Journal:  Neural Plast       Date:  2016-01-06       Impact factor: 3.599

Review 5.  Cannabinoid CB1 and CB2 Receptor Signaling and Bias.

Authors:  Mikkel Søes Ibsen; Mark Connor; Michelle Glass
Journal:  Cannabis Cannabinoid Res       Date:  2017-03-01

6.  Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors.

Authors:  Beata Bystrowska; Małgorzata Frankowska; Irena Smaga; Lucyna Pomierny-Chamioło; Małgorzata Filip
Journal:  Neurotox Res       Date:  2018-05-12       Impact factor: 3.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.